Induction of apoptosis by topotecan: implications for the treatment of leukemia.
Topotecan is a topoisomerase I inhibitor with activity against acute leukemia. Two phase I studies using infusional topotecan as a single agent demonstrated that the dose-limiting toxicity of topotecan in hematologic malignancies is mucositis; similar toxicity was observed in a phase I study of topotecan in combination with cytarabine. In the latter study, the percentage of bone marrow cells in S-phase correlated with response to therapy. Further studies of topotecan-based regimens in acute leukemia are indicated.
Seiter
K
K
Department of Medicine, New York Medical College, Valhalla, USA.
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology*; D059004:Topoisomerase I Inhibitors; D019772:Topotecan / Q000494:pharmacology* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D019772:Topotecan